Eva Ondrouskova

Brno, JM, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas.

High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas.

Journal: HemaSphere
Published: March 26, 2026

Leveraging a spectrum of cytogenomics methods for profiling complex karyotypes in chronic lymphocytic leukemia.

Leveraging a spectrum of cytogenomics methods for profiling complex karyotypes in chronic lymphocytic leukemia.

Journal: Human genomics
Published: December 31, 2025

Precision medicine in hemato-oncology - treatment of refractory multiple myeloma with massive extramedullary involvement using BRAF/ MEK inhibitors.

Precision medicine in hemato-oncology - treatment of refractory multiple myeloma with massive extramedullary involvement using BRAF/ MEK inhibitors.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Published: October 30, 2025

Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.

Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.

Journal: Blood cancer journal
Published: June 15, 2024

Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis.

Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis.

Journal: European journal of haematology
Published: March 22, 2024

Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs.

Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs.

Journal: Leukemia
Published: March 11, 2024

Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis of MYC Aberrations.

Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis of MYC Aberrations.

Journal: Frontiers in oncology
Published: January 21, 2022

Very rare near-haploid acute lymphoblastic leukemia resistant to immunotherapy and CAR-T therapy in 19-year-old male patient.

Very rare near-haploid acute lymphoblastic leukemia resistant to immunotherapy and CAR-T therapy in 19-year-old male patient.

Journal: Clinical case reports
Published: October 28, 2021

Transcription factor c-Myb: novel prognostic factor in osteosarcoma.

Transcription factor c-Myb: novel prognostic factor in osteosarcoma.

Journal: Clinical & experimental metastasis
Published: August 26, 2021

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.

Journal: Blood
Published: October 18, 2020

ZEB1/miR-200c/AGR2: A New Regulatory Loop Modulating the Epithelial-Mesenchymal Transition in Lung Adenocarcinomas.

ZEB1/miR-200c/AGR2: A New Regulatory Loop Modulating the Epithelial-Mesenchymal Transition in Lung Adenocarcinomas.

Journal: Cancers
Published: May 15, 2020

Suppression of AGR2 in a TGF-β-induced Smad regulatory pathway mediates epithelial-mesenchymal transition.

Suppression of AGR2 in a TGF-β-induced Smad regulatory pathway mediates epithelial-mesenchymal transition.

Journal: BMC cancer
Published: February 14, 2017
Showing 1-12 of 21

Last Updated: 09/26/2026